Yes, Having Identical Discordant Results Two Years Ago Fundamentally Changes Management
The fact that she had the exact same serologic pattern (reactive treponemal screening, nonreactive RPR, negative TP-PA/TP-IgG) two years ago strongly indicates this is a false-positive treponemal screening test rather than active or past syphilis, and she does not require treatment.
Why This History Matters
The stability of this discordant pattern over two years is the critical diagnostic clue:
True syphilis serology evolves over time. If this were untreated early syphilis from two years ago, the RPR would have become reactive and titers would have risen. If this were treated syphilis, the treponemal test would have remained positive but the confirmatory TP-PA would be reactive 1, 2.
False-positive treponemal screening tests remain stable. Studies show that 23-32% of patients with reactive treponemal EIA/CIA but negative RPR and negative confirmatory treponemal tests (TP-PA or FTA-ABS) represent false-positive screening results, particularly in low-prevalence populations 1, 2.
The negative confirmatory treponemal test (TP-PA or TP-IgG) is decisive. When both the nontreponemal test (RPR) and a second, different treponemal test are negative, this pattern indicates the initial treponemal screening test is falsely reactive 1, 3, 2.
Algorithmic Approach to This Scenario
Step 1: Verify the Pattern is Truly Identical
- Confirm both time points show: Treponemal screening (+), RPR (-), Confirmatory treponemal test (-)
- Ensure the same or equivalent tests were used
Step 2: Clinical Assessment
- No treatment is indicated if she remains asymptomatic with no clinical signs of syphilis
- No history of documented syphilis exposure or treatment
- No high-risk sexual behaviors or new partners suggesting recent exposure
Step 3: Document and Counsel
- Document this as a persistent false-positive treponemal screening test
- Counsel that she does not have syphilis and does not need treatment
- Note in the medical record to prevent future unnecessary treatment
Step 4: Future Testing Strategy
- Do not repeat syphilis screening unless there is a specific new exposure or clinical indication
- If future screening is required (e.g., pregnancy, new sexual exposure), expect the same pattern and do not treat based on the screening test alone
Common Pitfalls to Avoid
Do not treat based on the reactive screening test alone. The CDC explicitly recommends against treatment when the confirmatory treponemal test (TP-PA) is negative, even if the screening treponemal test is reactive 2. Treatment in this scenario would be inappropriate and exposes the patient to unnecessary medication risks.
Do not order additional treponemal tests. Studies show that repeating serology in patients with this stable discordant pattern does not identify additional cases of syphilis 4. The two-year stability confirms the diagnosis of false-positive screening.
Recognize that false-positive treponemal screening tests occur in 1.7-2% of tested populations 1, 3, and are more common in low-prevalence settings where the positive predictive value of screening tests is lower 2.
The Evidence Behind This Recommendation
The 2011 CDC analysis of reverse sequence syphilis screening found that among sera with reactive treponemal EIA/CIA but nonreactive RPR, 31.6% were also nonreactive by confirmatory treponemal testing (TP-PA or FTA-ABS) 2. This rate was 2.9 times higher in low-prevalence populations, indicating false-positive screening results.
A Kaiser Permanente study of 21,623 patients found that among those with reactive treponemal CIA but negative RPR, 28% had negative TP-PA results 1. Importantly, 23% of these patients with the triple-negative pattern (CIA+/RPR-/TP-PA-) subsequently seroreverted to CIA-negative on repeat testing, confirming these were false-positive screening results.
The two-year stability of her results, combined with negative confirmatory testing, provides definitive evidence this is not syphilis. No treatment or further testing is warranted unless there is new clinical or epidemiologic indication.